tbuckley/cabot-search huggingface dataset:
Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.
Authors: Paolo Grassi, Ludovic S. Doucet, Palma Giglione, Viktor Gruenwald, Bohuslav Melichar, Luca Galli, Ugo De Giorgi, Annalisa Guida, Cinzia Ortega, Matteo Santoni, Aristotelis Bamias, Elena Verzoni, Andrea Necchi, Lisa Derosa, Hana Studentova, Monica Pacifici, Filippo G. De Braud, Camillo Porta, Bernard J. Escudier, Giuseppe Procopio
Journal: Journal of Clinical Oncology (2015)

4550 Background: Pancreatic metastases from renal cell carcinoma (PmRCC) are uncommon and their prognostic role in the era of targeted terapies (TTs) is not well defined. We evaluated the outcome of a cohort of PmRCC patients (pts) who were treated with either surgery and TTs Methods: PmRCC pts treated between 1993 and 2014 were identified from the databases of 11 European centers. Clinical records were retrospectively reviewed and clinical outcome was analyzed. Kaplan-Meier methods and log-rank test were used to evaluate progression-free survival (PFS) and overall survival (OS). Cox proportional hazard models were used to analyse covariates associated to OS Results: A total of 276 pts were evaluated. PmRCC were synchronous to the primary in 80 pts (29%). Pts treated with pancreatic local treatment (PLoT), including surgery, were 77 (28%) while pts receiving systemic treatment were 256 (93%). Pts with only PmRCC were 42 (15%) whereas lung (47%), lymph nodes (28%) and liver (23%) were the most common metastatic sites in the remaining pts. Most of pts (95%) received nephrectomy (Nx). Median time from Nx to PmRCC occurrence was 91 months (mo) (IQR 54-142). First-line TTs included: sunitinib (44%), sorafenib (12%), pazopanib (9%), interferon + bevacizumab (6%) and temsirolimus (1%); 37% of pts received cytokines and 53% received subsequent lines of TTs. Best response to first-line TTs were complete response (5%) partial response (40%) and stable disease (39%) with a disease control rate of 84% and a median PFS of 12 mo (IQR 10-14). Median OS (calculated from the time of PmRCC diagnosis to death) was 73 mo (IQR 61-86) with a 5-yr OS of 58%. Median OS for pts treated with PLoT was 106 mo (IQR 78-204) with a 5-yr OS of 75%. At univariate analysis MSKCC/Heng prognostic score (p= .0004), Nx (p= .0002) and PLoT (p= < .0001) were significantly associated with OS.At multivariate analysis these variables confirmed their prognostic role Conclusions: PmRCC are associated with long-term survival, usually occur many years after Nx and lead to an indolent growth thus initial observation might be an option for this pts subgroup. Surgery should be considered in oligometastatic pts while TTs are active in widespread disease
Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial.
Authors: Le-chi Ye, Yunshi Zhong, Tianshu Liu, Ye Wei, Li Ren, Dexiang Zhu, Xinyu Qin, Jia Fan, Jingwen Chen, Wenju Chang, Qi Lin, Jianmin Xu
Journal: Journal of Clinical Oncology (2013)

3610 Background: Recently, early tumor shrinkage (ETS) was reported to predict outcome in metastatic colorectal cancer treated with cetuximab (cet). This study was to evaluate the impact of ETS on long-term outcome in patients (pts) with wild-type-KRAS unresectable CLLM receiving cet plus chemotherapy (CT, FOLFIRI or mFOLFOX6). Methods: 138 pts treated in a randomized controlled trial (70 in armA received CT plus cet and 68 in armB received CT alone) previously reported (Jianmin et al, ESMO 2012, abstract-557, ClinicalTrials.gov, number NCT01564810) were included into this analysis. ETS was defined as a reduction of ≥20% in the sum of the longest diameters of target lesions compared to baseline at the first evaluation (8 weeks). Outcome measures were progression-free survival (PFS) and overall survival (OS). Results: 132 pts were available for evaluation, and ETS occurred more frequently in armA than that in armB (45/68 vs. 26/64, p= .003). Irrespective of treatment arm, pts achieved ETS were associated with longer OS (armA: 38.0 vs. 18.7months, p&lt; .001; armB 30.6 vs.17.7months, p= .003) and PFS (armA: 11.8 vs. 4.8months, p&lt; .001; armB 8.0 vs.4.6months, p= .001) when compared to pts with no-ETS. Among pts with ETS, there were statistic difference between armA and armB in terms of PFS (11.8 vs. 8.0months, p= .041) but not of OS (38.0 vs. 30.6months, p= .30); the converted resection rates for liver metastases were 40.0% (18/45) in armA and 19.2% (5/26) in armB, which were no significantly different (p= .072). For pts without liver surgery, pts observed ETS also gained an increased survival benefit over those no-ETS in armA with regards to OS (p= .01) and PFS (p&lt; .001) though it was not full certified in armB (OS: p= .054; PFS: p= .041). For pts in armA, cet-induced skin toxicity correlated with the occurrence of ETS (p= .048). In addition, cox regression for OS using indicated a hazard ratio of 0.39 (95%CI 0.21–0.72, p = .003). Conclusions: ETS ≥20% at 8 weeks may serve as a predictor of favorable outcome in pts with wild-type-KRAS CLLM receiving cet plus CT.
Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease
Authors: Giulia Renda, Fabrizio Ricci, Robert P. Giugliano, Raffaele De Caterina
Journal: Journal of the American College of Cardiology (2017)

Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist. Phase III trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral stenosis or mechanical heart valves, but variably included patients with other VHD and valve surgeries.This study aimed to determine relative safety and efficacy of NOACs in patients with VHD.We performed a meta-analysis of the 4 phase III AF trials of the currently available NOACs versus warfarin in patients with coexisting VHD to assess pooled estimates of relative risk (RR) and 95% confidence intervals (CIs) for stroke/systemic embolic events (SSEE), major bleeding, intracranial hemorrhage (ICH), and all-cause death.Compared with warfarin, the rate of SSEE in patients treated with higher-dose NOACs was lower and consistent among 13,585 patients with (RR: 0.70; 95% CI: 0.58 to 0.86) or 58,098 without VHD (RR: 0.84; 95% CI: 0.75 to 0.95; interaction p = 0.13). Major bleeding in patients on higher-dose NOACs versus warfarin was similar and consistent among patients with (RR: 0.93; 95% CI: 0.68 to 1.27) or without VHD (RR: 0.85; 95% CI: 0.70 to 1.02; interaction p = 0.63 for VHD/no-VHD difference). Intracranial hemorrhage was lower with higher-dose NOACs than with warfarin irrespective of VHD (RR: 0.47; 95% CI: 0.24 to 0.93, and 0.49; 95% CI: 0.41 to 059, respectively; interaction p = 0.91). No protective effect of higher-dose NOACs in preventing all-cause death seemed to be present in patients with VHD versus without VHD (RR:1.01; 95% CI: 0.90 to 1.14 vs. RR: 0.88; 95% CI: 0.82 to 0.94, respectively; interaction p = 0.03).High-dose NOACs provide overall efficacy and safety similar in AF patients with or without VHD.
SUCCESSFUL INTRA-AORTIC BALLOON PUMP-SUPPORTED PERCUTANEOUS CORONARY INTERVENTION IN A PATIENT WITH A LATE PRESENTING MYOCARDIAL INFARCTION, MULTIVESSEL CORONARY ARTERY DISEASE COMPLICATED BY HEPARIN-INDUCED THROMBOCYTOPENIA, BIVENTRICULAR THROMBUS, AND REFRACTORY VENTRICULAR ARRHYTHMIA
Authors: Mazen Albaghdadi, Sunu Thomas, Patrick T. Ellinor, Kenneth Rosenfield, Farouc Jaffer
Journal: Journal of the American College of Cardiology (2017)
Phase II study of induction chemotherapy with cisplatin (Cis) and gemcitabine (Gem) followed by concomitant Cis-Gem and thoracic radiation (RTX) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Authors: P. Driesen, L. Verbeke, C. Lonchay, M. Lambrechts, Y. Mentens, L. Carestia, J. Rosier, B. Colinet, N. Chouaki, K. J. Kraaij
Journal: Journal of Clinical Oncology (2009)

7550 Background: In the CALGB Study Cis with Gem followed by concomitant chemoradiation for inoperable LA-NSCLC was effective, however with significant toxicity (E. Vokes et al; JCO 20: 2002). The aim of this study was to improve tolerability by reducing the Gem dose during radiotherapy and adding one cycle of induction chemotherapy. Methods: Patients with histological proven stage IIIA and IIIB NSCLC were included in this study from 8/04 to 9/07. All patients were to receive 3 induction cycles (21 days) of Cis 80 mg/m2 d1 plus Gem 1250 mg/m2 over 30 minutes d1, 8. After a 3 weeks rest period, 2 cycles of concomitant chemoradiation Cis 80 mg/m2 d1, Gem 300 mg/m2 d1, 8 and RTX (about 60 Gy; 5 times 1,8 Gy fractions / week) were given. Results: A total of 49 patients, median age 63.4 yrs, 73.5% male, with Karnofsky performance status 80/85/90/100: 16.3% / 2.0% / 49.0% / 32.7% were entered. Disease stage IIIA/IIIB: 28.6% / 71.4%. Median dose intensity during chemoradiation Gem 98.4%, Cis 99.0% and radiation median total dose was 63 Gy. Number of grade 3/4 toxicities during induction chemotherapy (N=49): neutropenia 9/9, thrombocytopenia 4/1. Acute grade 3/4 toxicities during chemoradiation phase (N=31): neutropenia 4/0, thrombocytopenia 5/1, radiation esophagitis 4/0 and radiation pneumonitis 1/0. No toxic death. Tumor Response Rate of enrolled patients was 22 (44.9%) (95% CI: 30.7–59.8). Conclusions: Concurrent Cis Gem chemoradiation after Cis Gem induction is an active treatment for LA-NSCLC with managable toxicity. [Table: see text]
MORTALITY RATES AND COST OF HOSPITAL ADMISSIONS FOR SYNCOPE IN THE UNITED STATES
Authors: Ghanshyambhai Tulsibhai Savani, Vikas Singh, Alexis Rodriguez, Teshome Tegene, Mauricio Cohen, Carlos Alfonso, Raul Mitrani, Juan Viles-Gonzalez, Robert Myerburg, Jeffrey Goldberger
Journal: Journal of the American College of Cardiology (2017)
The influence of preoperative core biopsy on specimen volume in breast conserving therapy for breast cancer patients
Authors: A. Galid, A. Witt, E. Kubista
Journal: Journal of Clinical Oncology (2004)

795 Background: Preoperative core biopsy gives us important information on suspect lesions of the breast before surgery. Operative Management depends on this information. We wanted to know if preoperative core biopsy influences the specimen volume in breast cancer surgery Methods: Surgical specimens of 366 patients were analyzed retrospectively who underwent breast conserving surgery for breast cancer at the Department of Special Gynaecology -University Clinics of Vienna - throughout 1994 to 1998. All specimens were measured 3 dimensional macroscopically before frozen dissection. Results: 249 patients didn't undergo preoperative core biopsy which resulted in an average specimen volume of 135 cm3. Those 117 patients who received core biopsy before surgery had an average specimen volume of 182 cm3. This shows statistical significance (p=0,004). Tumour size was well balanced in both groups. Conclusions: Preoperative core biopsy influences surgical specimen volume in breast cancer patients who undergo breast conserving therapy. Average specimen volume increases significantly if the surgeon gets his information before surgery. We conclude that preoperative core biopsy should be performed in every suspect breast lesion before surgery in order to achieve more local disease control. No significant financial relationships to disclose.
The Effects of Different Formulations of Oral Contraceptive Agents on Lipid and Carbohydrate Metabolism
Authors: Ian F. Godsland, David Crook, Ruth Simpson, Tony Proudler, Carl Felton, Belinda Lees, Victor Anyaoku, Maxeen Devenport, Victor Wynn
Journal: New England Journal of Medicine (1990)

Oral contraceptives can induce changes in lipid and carbohydrate metabolism similar to those associated with an increased risk of coronary heart disease, including increased serum triglyceride, low-density lipoprotein (LDL) cholesterol, and insulin levels and decreased high-density lipoprotein (HDL) cholesterol levels. In this study, we examined whether modification of the type or dose of progestin in oral-contraceptive preparations diminishes these changes.We measured plasma lipoprotein levels and performed oral glucose-tolerance tests in a cross section of 1060 women who took one of nine types of oral contraceptives for at least three months and 418 women who took none. Seven of the contraceptive formulations contained various doses and types of progestin: levonorgestrel in low (150 micrograms), high (250 micrograms), and triphasic (50 to 125 micrograms) doses; norethindrone in low (500 micrograms), high (1000 micrograms), and triphasic (500 to 1000 micrograms) doses; and a new progestin, desogestrel, in one dose (150 micrograms). All seven contained 30 to 40 micrograms of ethinyl estradiol. Two additional formulations contained progestin alone.As compared with controls, women taking combination drugs did not have increased serum total cholesterol levels but did have increases of 13 to 75 percent in fasting triglyceride levels. Levels of LDL cholesterol were reduced by 14 percent in women taking the combination containing desogestrel and by 12 percent in those taking low-dose norethindrone. Levels of HDL cholesterol were lowered by 5 percent and 16 percent by the combinations containing low-dose and high-dose levonorgestrel, respectively; these decreases were due to reductions of 29 percent and 43 percent, respectively, in the levels of HDL subclass 2. The combination pill containing high-dose norethindrone did not affect HDL cholesterol levels, whereas that containing low-dose norethindrone increased HDL cholesterol levels by 10 percent. The desogestrel combination increased HDL cholesterol levels by 12 percent. Levels of apolipoproteins A-I, A-II, and B were generally increased by combination drugs. Depending on the dose and type of progestin, combination drugs were associated with plasma glucose levels on the glucose-tolerance test that were 43 to 61 percent higher than in controls, insulin responses 12 to 40 percent higher, and C-peptide responses 18 to 45 percent higher. Progestin-only formulations had only minor metabolic effects.The appropriate dose and type of progestin may reduce the adverse effects of oral contraceptives on many metabolic markers of risk for coronary heart disease. Progestin-only formulations or combinations containing desogestrel or low-dose norethindrone were associated wtih the most favorable profiles.
THERAPEUTIC HYPOTHERMIA IN POST-CARDIAC ARREST SYNDROME: ROLE OF NEURON-SPECIFIC ENOLASE AS EARLY PREDICTOR OF NEUROLOGICAL STATUS AT DISCHARGE
Authors: Rodolfo San Antonio Dharandas, Gustavo Jimenez, Eduardo Flores, Gala Caixal, Guillem Caldentey, Marco Hernandez Enriquez, Paula Sanchez Somonte, Xavier Freixa, Monica Masotti, Manel Sabate
Journal: Journal of the American College of Cardiology (2017)
INCREASED SUBCLINICAL SYSTEMIC AND VASCULAR INFLAMMATION IN FAMILIAL COMBINED HYPERLIPIDEMIA COMPARED TO HETEROZYGOUS HYPERCHOLESTEROLEMIA: INSIGHTS FROM A POSITRON EMISSION TOMOGRAPHY STUDY
Authors: Koutagiar Peter Iosif, Konstantinos Toutouzas, Georgios Benetos, Ioannis Skoumas, Pavlos Kafouris, Alexandros Georgakopoulos, Spyridon Galanakos, Nikoletta Pianou, Mahmoud Abdelrasoul, Angeliki Rigatou, George Spyrou, Constadina Aggeli, Eleftherios Tsiamis, Dimitris Tousoulis, Constantinos Anagnostopoulos
Journal: Journal of the American College of Cardiology (2017)
CREB/ATF Family Protein Expression States in AML: Active CREB1, but Not ATF Is an Adverse Prognostic Factor
Authors: Steven M. Kornblau, Chenyue W Hu, Yihua Qiu, Suk Young Yoo, Kavita Chauhan, Elias Jabbour, Farhad Ravandi, Kevin Coombes, Amina A Qutub
Journal: Blood (2014)
IMPACT OF OBSTRUCTIVE SLEEP APNEA SEVERITY ON CARDIAC EVENTS IN PATIENTS WITH NORMAL OR PROLONGED VENTRICULAR REPOLARIZATION
Authors: Lauren Richards, Beneet Pandey, Tadele Mengesha, Samian Sulaiman, Zoe Heis, Michael N. Katzoff, Indrajit Choudhuri, Imran Niazi, A. Jamil Tajik, Arshad Jahangir
Journal: Journal of the American College of Cardiology (2017)
VITAMIN D LEVELS AND AUTOANTIBODIES IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA): IMPLICATIONS FOR CARDIOVASCULAR DISEASE
Authors: Karola Jering, Di Zhao, Eliseo Guallar, Ian de Boer, Bryan Kestenbaum, Pamela Lutsey, Moyses Szklo, Darcy Majka, Erin Michos
Journal: Journal of the American College of Cardiology (2017)
Second Hematopoietic SCT for Thalassemia Major: Improved Clinical Outcomes with a Treosulfan Based Conditioning Regimen
Authors: Vikram Mathews, Anu Korula, Nisham PN, Anup Joseph Devasia, Fouzia NA, Kavitha M Lakshmi, Aby Abraham, Biju George, Alok Srivastava
Journal: Blood (2016)
PROGNOSTIC VALUE OF PROTEIN BIOMARKERS PREDICT RISK OF CORONARY HEART DISEASE EVENTS: RESULTS FROM MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Rine Nakanishi, B ů ž ková Petra, Douglas Harrington, Kazuhiro Osawa, Yanting Luo, Indre Ceponiene, Sina Rahmani, Negin Nezarat, Hong Qi, Matthew Budoff
Journal: Journal of the American College of Cardiology (2017)
HYPOTHYROIDISM MODULATES MITOCHONDRIAL CALCIUM UNIPORTER EXPRESSION AND CAUSES CARDIOPROTECTION DECRESING MITOCHONDRIAL PERMEABILITY TRANSITION PORE OPENING
Authors: Hector Chapoy, Yuriana Oropeza-Almazan, Ana Gutiérrez-Rodríguez, Gerardo Garcia-Rivas
Journal: Journal of the American College of Cardiology (2017)
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: Safety and activity results of our clinical experience
Authors: B. Adamo, T. Franchina, N. Denaro, C. Garipoli, G. Ferraro, R. Briguglio, G. R. Ricciardi, P. Gambadauro, G. Ferrandina, V. Adamo
Journal: Journal of Clinical Oncology (2009)

e12005 Background: Elderly breast cancer patients have an increased risk of toxicity from chemotherapy, especially from anthracycline-based regimens. Pegylated liposomal doxorubicin (PLD) has shown a better tolerability profile also in combination with gemcitabine (GEM), as evidenced in several phase II trials. The aim of this study is to retrospectively evaluate the safety and activity of this combination in chemo-naïve or pre-treated elderly patients with advanced breast cancer. Methods: From January 2006 to March 2008, 39 patients (pts) with age ≥ 65 received, at our institution, PLD 25 mg/m 2 (day 1, q21) and GEM 800 mg/m 2 (days 1 and 8, q21). Median age was 72 (range, 65–79). ECOG PS was 0/1/2 in 14/23/2 pts, respectively. 12 pts (31%) were chemo-naïve, 20 (51%) received prior adjuvant anthracycline-based regimens, and 7 (18%) received other chemotherapies. PLD-GEM combination was administered as first line in 35 pts (90%). Median left ventricular ejection fraction (LVEF) at baseline was 61% (range, 50%-75%). 28 patients (72%) had metastatic disease: 10 in liver, 6 in lung, 2 in skin, and 10 in multiple sites. Estrogen receptor was positive in 32 pts (82%); HER-2+ in 5 pts; 7 pts were triple negative. Results: A total of 206 cycles were administered with a mean number of cycles per patient of 5.2 (range, 3–12). Grade 3–4 neutropenia occurred in 4 (10%) and 3 patients (8%), respectively; grade 3 anemia in two pts (5%). Non-hematological toxicity was mild, with 5 cases (13%) of grade 3 mucositis, and 2 cases (5%) of grade 2 palmar-plantar erythrodysesthesia syndrome. No modifications in LVEF or toxic deaths were documented. We observed 1 CR (2.5%) and 11 PR (28.2%). Eighteen (44%) patients experienced SD for 16 weeks and an overall clinical benefit of 76.8%. Conclusions: The combination of PLD and GEM has a favorable tolerability and a safety profile with an evident clinical benefit and should represent an interesting treatment option in elderly women with advanced breast cancer. No significant financial relationships to disclose.
Quality of life and cognitive dysfunction in breast cancer survivors on a feasibility study of donepezil versus placebo.
Authors: Julia Lawrence, Leah Griffin, Steve Rapp, Michael J. Messino, Ernie P. Balcueva, Amarinthia E. Curtis, David L. Groteluschen, Thomas A. Samuel, Glenn Lesser, Doug Case, Edward G. Shaw
Journal: Journal of Clinical Oncology (2014)

9516 Background: Breast cancer survivors report long term cognitive and quality of life effects due to cancer and chemotherapy. Cognitive enhancers (donepezil) could be a treatment option. We conducted a randomized, placebo-controlled phase II study to determine the feasibility of a larger phase III trial to improve cognitive function in breast cancer survivors with self-reported cognitive problems 1 to 5 years following chemotherapy. Methods: 62 patients were randomized to receive donepezil (5mg x 6 weeks + 10 mg x 18 weeks) or placebo. Participants completed a comprehensive battery of neurocognitive tests and questionnaires measuring cognitive symptoms, mood, fatigue, sleep disturbance and quality of life at baseline, 24, and 36 weeks post randomization. Women were screened for cognitive impairment with the FACT-Cog Perceived Cognitive Impairment subscale and were eligible if they scored <63. Results: The study opened at 16 sites and enrolled 62 women over 6 months (accrual rate of 10.2subjects/month). Ages ranged from 39 to 79 years (median of 56 years). 90% of the women were Caucasian, 87% were overweight or obese, and 65% had completed chemotherapy 1 and 3 years ago. Baseline FACT-PCI scores ranged from 5 to 61; 34 (55%) had scores < 30. Retention was 84% at 12 weeks and 76% at 24 weeks. Adherence to donepezil while on study ranged from 88% to 100%. Scores on the quality of life measures (SF-36, FACIT-Fatigue, PROMIS-7, Epworth Sleepiness Scale, Beck Depression Index and the Beck Anxiety Index) improved over the 24 weeks of treatment in both groups. In addition, scores for most of the neurocognitive tests improved over time in both arms. The study was not powered to detect differences in QOL or neurocognitive performance between arms, but positive trends in favor of Donepezil were noted for total recall and discrimination on the HVLT (Hopkins Verbal Learning Test) (p=0.08 and 0.02, respectively). Conclusions: In this cohort of breast cancer survivors reporting cognitive problems 1-5 years following chemotherapy, we had excellent accrual, retention and adherence. QOL and HVLT improved over 24 weeks. These data support a phase III trial of donepezil for the treatment of cognitive dysfunction in this population. Clinical trial information: NCT01466270.
CLEVEDIPINE AS A THERAPEUTIC AND COST-EFFECTIVE ALTERNATIVE TO SODIUM NITROPRUSSIDE IN PATIENTS WITH AORTIC DISSECTION
Authors: Carlos Leon Alviar, Alejandra Gutierrez, Leslie Cho, Amar Krishnaswamy, Amr Saleh, A. Lincoff, Eric Roselli, Michael Militello, Venu Menon
Journal: Journal of the American College of Cardiology (2017)
NEW INSIGHTS AND NEW HOPE FOR PULMONARY ARTERIAL HYPERTENSION: NATRIURETIC PEPTIDES CLEARANCE RECEPTOR AS A NOVEL THERAPEUTIC TARGET FOR A COMPLEX DISEASE
Authors: Emmanuel Egom, Tiam Feridooni, Rebabonye Pharithi, Vincent Maher, Yassine El Hiani, Kishore Pasumarthi, Hilaire Ribama
Journal: Journal of the American College of Cardiology (2017)
IMPACT OF PERCUTANEOUS CORONARY INTERVENTION FOR CHRONIC TOTAL OCCLUSION PATIENTS WITH NEAR-NORMAL LEFT VENTRICULAR FUNCTION
Authors: Seung-Woon Rha, Hu Li, Byoung Geol Choi, Se Yeon Choi, Jae Kyeong Byun, Min Shim, Jun Hyuk Kang, Woo Hyeun Kim, Sung Hun Park, Eun Jin Park, Jah Yeon Choi, Sunki Lee, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong-Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2017)
The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study
Authors: Kim Klein, Martin Zimmermann, Berna Beverloo, Christine von Neuhoff, Valerie De Haas, Romy van Weelderen, Susana C. Raimondi, Jacqueline Cloos, Jonas Abrahamsson, Yves Bertrand, Michael Dworzak, Sarah Elitzur, Alcira Fynn, Brenda Gibson, Shau Yin Ha, Christine Harrison, Henrik Hasle, Guy Leverger, Alexey Maschan, Bassem I. Razzouk, Dirk Reinhardt, Carmelo Rizzari, Petr Smisek, Ursula Creutzig, Gertjan J.L. Kaspers
Journal: Blood (2016)